Published on October 16, 2017
Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant. Dr. Keating also explains the role of monoclonal antibodies.
This Ask the Expert series is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie and Genentech for their support.
Thank you, Andrew and team, for creating the best information source on the web for CLL!